Bayer HealthCare AG
ExonHit Therapeutics
Gene Network Sciences
Genstruct, Inc.
Institut Curie
Merck & Co., Inc.
Murex Pharmaceuticals
The National Cancer Institute
UCB-Celltech
University of Oklahoma
Vanderbilt University

A sample of scientific publications made using Ariadne products is available in Publications.

“Bayer HealthCare recognizes the importance of using pathway analysis tools for interpretation of experimental results and hypotheses validation. But to make these tools truly efficient, we need an internal integrated database of pathways and molecular networks, containing all most recent information. We have chosen MedScan for its advanced natural language processing algorithm, well known for high recovery rate and accuracy, and its ease of integration with our bioinformatics systems.” - Michael Seewald, Bioinformatician.

“We have customized Pathway Studio’s natural language processing capability to extend the data set provided by Ariadne with alternative splicing information retrieved from literature sources.  Pathway Studio is a valuable tool in our standard research process." - Dr. John Jaskowiak, Executive VP of Business Development at ExonHit.

“PathwayStudio Central is an efficient and effective tool to help integrate the latest pathway-related knowledge scattered throughout scientific publications with our pre-clinical and clinical models,” - Jeffrey Fox, Ph.D., vice president of research of GNS.

“The accuracy of our assertions is one of our highest priorities. MedScan TextMiner, with its unique Natural Language Processing engine, will improve our ability to apply Knowledge Assembly to the extraction of molecular interaction information from the scientific literature.” - Keith O. Elliston, Ph.D., President and CEO of Genstruct.

“PathwayStudio will be utilized in our research projects aimed at understanding and stopping tumoral progression, in particular for the elucidation of the biological pathways that are responsible of cell deregulation, such as perturbation in apoptosis, proliferation, and differentiation. One of our main purposes is to better classify, diagnose and prognose tumors, and to adapt treatments to individual patients.” - Emmanuel Barillot, Director of Bioinformatics at Institut Curie.

“It’s hard to overestimate the importance of Pathway Studio in our development of cancer therapies based on patients’ individual gene expression data. Pathway Studio will accelerate our development efforts as well as help to further increase the safety of our products.” -David Shanahan, President and CEO of Murex Pharmaceuticals.

"We will perform scientific evaluation of pathway expansion and microarray data analysis algorithms available in Pathway Studio. Then we will build up a collection of cancer-related pathways using its built-in ResNet database and advanced pathway reconstruction and literature mining tools." - Dr. Dee Wu, an associate professor at the OU Health Sciences Center.

“We evaluated various pathway analysis packages and were impressed by Pathway Studio’s graphics and ease of use. Most impressive is the MedScan Technology that allows our researchers to extract relationships from the latest publications and add them to the large body of knowledge in the packaged database. The ability to instantly update the database with selected information is of paramount importance in cancer research." - Dr. Lynn Matrisian, Chair of the Department of Cancer Biology at Vanderbilt University.